Neoral use in the renal transplant recipient.

This review and critical analysis of current trends of immunosuppression management in pediatric transplantation provides evidence and support for the continued role of Neoral as an indispensable part of immunosuppressive protocols. CyA formulation influences clinical outcomes such as acute rejection, as confirmed by several multicenter studies. The CyA microemulsion formulation reduces pharmacokinetic variability and its consequent impact on outcomes over the long term. An advanced TDM strategy can improve the effectiveness and safety of immunosuppression in both de novo and maintenance renal transplant patients. There are potential risks resulting from CyA withdrawal strategies. Neoral is an indispensable part of combination protocols in renal transplantation.

[1]  P. Greig,et al.  Neoral without intravenous cyclosporine in liver transplantation. , 1997, Transplantation proceedings.

[2]  W. Bechstein,et al.  Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application? , 1996, Transplantation proceedings.

[3]  D. Rush,et al.  A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. , 1996, Transplantation.

[4]  P. Keown,et al.  Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. , 1998, Kidney international.

[5]  P. Greig,et al.  A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation. , 1996, Transplantation.

[6]  R. Loertscher,et al.  Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group. , 1998, Transplantation.

[7]  R. Tardanico,et al.  Neoral reduces the incidence of acute rejection after renal transplantation. , 1998, Transplantation proceedings.

[8]  P. Belitsky,et al.  Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve. , 1999, Transplantation proceedings.

[9]  B. Kahan.  FTY720: a new immunosuppressive agent with novel mechanism(s) of action. , 1998, Transplantation proceedings.

[10]  G. Remuzzi,et al.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. , 1996, Transplantation.

[11]  P. Halloran,et al.  Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). , 1998, Transplantation proceedings.

[12]  B. Kahan.  Drug therapy: cyclosporine , 1989 .

[13]  M. Pescovitz,et al.  The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group. , 1996, Transplantation.

[14]  C. Groth.  The European experience with mycophenolate mofetil. European Mycophenolate Mofetil Cooperative Study Group. , 1996, Transplantation proceedings.

[15]  M. Castagneto,et al.  Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation. , 1998, Transplantation proceedings.

[16]  F. Scolari,et al.  Trough cyclosporine concentration variability. , 1998, Transplantation proceedings.

[17]  S. Hariharan,et al.  Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. , 1994, Transplantation proceedings.

[18]  J. Soulillou,et al.  Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients , 1997, The Lancet.

[19]  M. Pescovitz,et al.  Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group. , 1997, Transplantation.

[20]  B. Kahan,et al.  Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation , 1993, Clinical pharmacology and therapeutics.

[21]  G. Yee,et al.  Pharmacokinetic Drug Interactions with Cyclosporin (Part II) , 1990, Clinical pharmacokinetics.

[22]  B. Kahan.  High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. , 1998, Transplantation proceedings.

[23]  E. Mueller,et al.  Cyclosporine microemulsion formulation (Neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships. , 1998, Transplantation proceedings.

[24]  D. Urbauer,et al.  Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. , 1996, Transplantation.

[25]  J. Lodge,et al.  Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group. , 1997, Transplantation proceedings.

[26]  R. Venkataramanan,et al.  Clinical Pharmacokinetics of Cyclosporin , 1986, Clinical pharmacokinetics.

[27]  J. Kallen,et al.  Chemical modification of rapamycin: the discovery of SDZ RAD. , 1998, Transplantation proceedings.

[28]  J. Alexander,et al.  Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. , 1995, Transplantation.

[29]  B. Goldsmith,et al.  Effects of Carbamazepine on Cyclosporine Metabolism in Pediatric Renal Transplant Recipients , 1995, Pharmacotherapy.

[30]  B. Kahan,et al.  Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. , 1996, Transplantation proceedings.

[31]  L. Heslet,et al.  Induction of immunosuppression by microemulsion cyclosporine in liver transplantation. , 1996, Transplantation.

[32]  S. Light,et al.  Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. , 1998, Transplantation proceedings.

[33]  J. Kovarik,et al.  Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. , 1996, Transplantation.

[34]  K. West,et al.  Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. , 1999, Transplantation.